expertise may be relevant to questions about robot-mounted sensors, workplace monitoring, worker-worn sensors, alarm performance, sensor data quality, and the interpretation and use of those data. Current and recent NIOSH work includes:

- Surveillance of robot-related injury claims and studies of how robot motion and design can affect perceived safety, trust, workload, worker behavior, and task performance.
- Human-robot interaction studies including robot-arm and mobile-robot studies that examine how movement speed, trajectory, design, and interaction geometry shape perceived safety, trust, workload, worker behavior, and task performance.
- Various approaches to visibility, separation, and collision avoidance.
- Research in application areas such as construction that also considers how changing work conditions, sensing, communication, software, and work organization can affect safe implementation.

NIOSH is exploring occupational safety and health applications of humanoid robots. Humanoid robots may combine bipedal or other human-like mobility with manipulation, perception, remote operation, autonomous functions, and software that can be updated or adapted. These characteristics may create questions that are not fully answered by experience with fixed industrial robots or other established robot types. NIOSH is interested in evidence about both potential worker-safety benefits and potential hazards, including how robot capabilities, work organization, and workplace conditions affect risk. Please consider addressing these questions or provide other comments you deem relevant.

(1) What tasks could humanoid robots perform, and how might their safety risks and benefits differ from those of other robots?

(2) How might humanoid robots affect workers' awareness, trust, workload, training, and safety behaviors?

(3) What hazards should be prioritized, and what injury, near-miss, or exposure data would help identify risks to workers?

(4) What tests or measures are needed to assess humanoid robot safety in realistic work conditions?

(5) What factors help or hinder organizations in adopting and sustaining effective safety practices for humanoid robots?

(6) How could sensors or wearables support worker safety around humanoid robots?

(7) Which robot design features and safety controls should be prioritized?

(8) What research, standards, or partnerships should NIOSH prioritize to support safe human-robot interaction?

John J. Howard,

Director, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, Department of Health and Human Services.

[FR Doc. 2026–23799 Filed 11–20–26; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2026–N–5829]

Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Extralabel Drug Use in Animals

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

DATES: Submit written comments (including recommendations) on the collection of information by December 23, 2026.

ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written comments be submitted to *https://www.reginfo.gov/public/do/PRAMain.* Find this particular information collection by selecting ''Currently under Review—Open for Public Comments'' or by using the search function. The OMB control number for this information collection is 0910–0325. Also include the FDA docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Kelly Covington, Office of Operations, Food and Drug Administration, Three White Flint North, 10A–12M, 11601 Landsdown St., North Bethesda, MD 20852, 240–402–5661, *PRAStaff@fda.hhs.gov.*

SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance.

Extralabel Drug Use in Animals—21 CFR 530

OMB Control Number 0910–0325—Extension

This information collection supports Food and Drug Administration (FDA, us or we) implementation of section 512 of the Federal Food, Drug and Cosmetic Act (FD&C Act) (21 U.S.C. 360b), which governs new animal drugs. Agency regulations in 21 CFR part 530, permit FDA, if we find that there is a reasonable probability that the extralabel use of an animal drug may present a risk to public health, to establish a safe level for a residue from the extralabel use of the drug, and to require the development of an analytical method for the detection of residues above that established safe level. This requirement is codified at 21 CFR 530.22(b). Although to date, we have not established a safe level for a residue from the extralabel use of any new animal drug and, therefore, have not required the development of analytical methodology, we believe that there may be instances when analytical methodology will be required. We are, therefore, estimating the reporting burden based on two methods being required annually. The requirement to establish an analytical method may be fulfilled by any interested person. We believe that the sponsor of the drug will be willing to develop the method in most cases. Alternatively, FDA, the sponsor, and perhaps a third party may cooperatively arrange for method development. The respondents may be sponsors of new animal drugs, State, or Federal and/or State Agencies, academia, or individuals.

In the **Federal Register** of June 18, 2026 (91 FR 36868), FDA published a 60-day notice requesting public comment on the proposed collection of information. No comments were received.

FDA estimates the burden of this collection of information as follows:

TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN [1]

21 CFR part; activity	Number of respondents	Number of responses per respondent	Total annual responses	Average burden per response	Total hours
530.22(b); Submission(s) of analytical method	2	1	2	4,160	8,320

[1] There are no capital costs or operating and maintenance costs associated with this collection of information.

Based on a review of the information collection since our last request for OMB approval, we have made no adjustments to our burden estimate.

Grace R. Graham,

Deputy Commissioner for Policy, Legislation, and International Affairs.

[FR Doc. 2026–23740 Filed 11–20–26; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2026–N–13368]

Tobacco Products Scientific Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; establishment of a public docket; request for comments.

SUMMARY: The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Tobacco Products Scientific Advisory Committee (TPSAC, the Committee). The general function of the Committee is to provide advice and recommendations to FDA on regulatory issues related to tobacco products. The meeting will be open to the public. FDA is establishing a docket for public comments related to the TPSAC meeting.

DATES: The meeting will be held on January 21, 2027, from 9 a.m. to 4:30 p.m. Eastern Time (ET).

ADDRESSES: FDA White Oak Campus, 10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great Room (Rm. 1503), Silver Spring, MD 20993–0002. The public will also have the option to participate in person, and the advisory committee meeting will be heard, viewed, captioned, and recorded through an online teleconferencing and/or video conferencing platform.

Answers to commonly asked questions about FDA advisory committee (AC) meetings, including information regarding special accommodations due to a disability, visitor parking, and transportation may be accessed at: *https://www.fda.gov/AdvisoryCommittees/default.htm.*

FDA is establishing a docket for public comments on this meeting. The docket number is FDA–2026–N–13368. The docket will close on January 12, 2027. Comments received on or before January 12, 2027, will be provided to the Committee. The electronic filing system will accept comments until 11:59 p.m. ET at the end of January 12, 2027. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are received on or before that date. In the event that the meeting is cancelled, FDA will update its website with information on the rescheduled date and will continue to evaluate any relevant information, and consider any comments submitted to the docket, as appropriate.

As required under Section 911 of the FD&C Act, FDA also is accepting public comments on the Modified Risk Tobacco Product Application: Renewal Applications for VLN® King and VLN® Menthol King, Cigarette Products Submitted by 22nd Century Group Inc. via Docket No. FDA–2019–N–0994–0230, which is separate from the docket intended for comments for TPSAC: FDA–2026–N–13368.

- For comments to be considered as part of scientific review for the MRTPA, submit comments to FDA–2019–N–0994–0230. Comments in this docket will not be referred to the Committee.
- For comments to be considered by the TPSAC as part of the January 21, 2027, TPSAC meeting discussion, submit comments to FDA–2026–N–13368 by January 12, 2027, as noted above.
- For comments to be considered as part of the scientific review for the MRTPA and the January 21, 2027, TSPAC meeting discussion, submit comments to both dockets.

You may submit comments as follows:

Electronic Submissions

Submit electronic comments in the following way:

- *Federal eRulemaking Portal: https://www.regulations.gov.* Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to *https://www.regulations.gov* will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on *https://www.regulations.gov.*
- If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see ''Written/Paper Submissions'' and ''Instructions'').

Written/Paper Submissions

Submit written/paper submissions as follows:

- *Mail/Hand Delivery/Courier (for written/paper submissions):* Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
- For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in ''Instructions.''

Instructions: All submissions received must include the Docket No. FDA–2026–N–13368 for ''Tobacco Products Scientific Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments.'' Received comments, those filed in a timely manner (see **ADDRESSES**), will be placed in the docket and, except for those submitted as ''Confidential Submissions,'' publicly viewable at *https://www.regulations.gov* or at the Dockets Management Staff between 9 a.m. and 4 p.m. ET, Monday through Friday, 240–402–7500.

- Confidential Submissions—To submit a comment with confidential information that you do not wish to be